Alexion Pharmaceuticals Company Profile (NASDAQ:ALXN)

About Alexion Pharmaceuticals

Alexion Pharmaceuticals logoAlexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. The Company operates through innovation, development and commercialization of life-transforming therapeutic products segment. The Company's marketed products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company's clinical programs include Soliris (eculizumab), ALXN 1101, ALXN 1007, SBC-103, ALXN 1210 and ALXN 5500. It offers Soliris for patients with either paroxysmal nocturnal hemoglobinuria (PNH), a life-threatening and ultra-rare genetic blood disorder, or atypical hemolytic uremic syndrome (aHUS), a life-threatening and ultra-rare genetic disease. Strensiq is a targeted enzyme replacement therapy. It offers Kanuma for the treatment of patients with Lysosomal Acid Lipase Deficiency (LAL-D). ALXN 1007 is a humanized antibody designed to target inflammatory disorders.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: ALXN
  • CUSIP: 01535110
Key Metrics:
  • Previous Close: $122.47
  • 50 Day Moving Average: $125.01
  • 200 Day Moving Average: $133.82
  • 52-Week Range: $224,248,000.00 - $110.56
  • Trailing P/E Ratio: 302.16
  • Foreward P/E Ratio: 20.59
  • P/E Growth: 1.45
  • Market Cap: $26.97B
  • Outstanding Shares: 224,248,000
  • Beta: 1.33
  • Net Margins: 3.19%
  • Return on Equity: 10.02%
  • Return on Assets: 6.30%
  • Debt-to-Equity Ratio: 0.41%
  • Current Ratio: 3.59%
  • Quick Ratio: 3.09%
Additional Links:
Companies Related to Alexion Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Alexion Pharmaceuticals (NASDAQ:ALXN) (?)
Ratings Breakdown: 1 Sell Rating, 6 Hold Ratings, 13 Buy Ratings
Consensus Rating:Buy (Score: 2.60)
Consensus Price Target: $178.63 (48.54% upside)

Analysts' Ratings History for Alexion Pharmaceuticals (NASDAQ:ALXN)
DateFirmActionRatingPrice TargetDetails
10/7/2016FBR & CoReiterated RatingSellView Rating Details
10/4/2016Brean CapitalInitiated CoverageBuy$221.00View Rating Details
9/26/2016Leerink SwannBoost Price TargetOutperform$210.00 -> $211.00View Rating Details
9/23/2016Jefferies GroupLower Price TargetHold$140.00 -> $120.00View Rating Details
9/22/2016WedbushInitiated CoverageNeutral$132.00View Rating Details
9/22/2016Cowen and CompanyReiterated RatingBuyView Rating Details
9/20/2016Citigroup Inc.Boost Price TargetBuy$154.00 -> $155.00View Rating Details
8/16/2016Piper Jaffray Cos.Reiterated RatingOverweight$185.00View Rating Details
7/29/2016Barclays PLCLower Price TargetEqual Weight$165.00 -> $150.00View Rating Details
7/29/2016Stifel NicolausLower Price TargetBuy$195.00 -> $182.00View Rating Details
7/13/2016SunTrust Banks Inc.Lower Price TargetBuy$220.00 -> $197.00View Rating Details
7/12/2016Royal Bank Of CanadaInitiated CoverageOutperform$188.00View Rating Details
7/11/2016Credit Suisse Group AGUpgradeNeutral -> Outperform$186.00 -> $165.00View Rating Details
6/29/2016Morgan StanleyReiterated RatingOverweightView Rating Details
6/13/2016Robert W. BairdReiterated RatingNeutral$145.00View Rating Details
6/6/2016Bank of America Corp.Reiterated RatingBuyView Rating Details
6/7/2016Oppenheimer Holdings Inc.Reiterated RatingBuy$228.00 -> $221.00View Rating Details
6/7/2016BMO Capital MarketsReiterated RatingBuy$168.00 -> $160.00View Rating Details
2/22/2016Goldman Sachs Group Inc.Lower Price Target$186.00 -> $168.00View Rating Details
2/4/2016JPMorgan Chase & Co.Lower Price Target$225.00 -> $185.00View Rating Details
1/7/2016BTIG ResearchDowngradeBuy -> NeutralView Rating Details
10/13/2015Raymond James Financial Inc.Reiterated RatingStrong-Buy$225.00View Rating Details
8/4/2015Deutsche Bank AGReiterated RatingBuy$215.00View Rating Details
6/23/2015Sanford C. BernsteinSet Price TargetBuy$267.00View Rating Details
5/7/2015NomuraUpgradeNeutral -> Buy$222.00 -> $246.00View Rating Details
(Data available from 10/23/2014 forward)


Earnings History for Alexion Pharmaceuticals (NASDAQ:ALXN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/27/2016Q316$1.17$787.07 millionN/AView Earnings Details
7/28/2016Q216$1.17$1.13$743.18 million$753.00 millionViewListenView Earnings Details
4/28/2016Q116$1.13$1.11$710.98 million$701.00 millionViewListenView Earnings Details
2/3/2016Q415$1.10$1.13$703.42 million$701.00 millionViewN/AView Earnings Details
10/29/2015Q315$1.01$1.16$668.33 million$666.60 millionViewListenView Earnings Details
7/30/2015Q215$1.39$1.44$628.03 million$636.00 millionViewListenView Earnings Details
4/23/2015Q115$1.32$1.28$594.40 million$600.30 millionViewN/AView Earnings Details
1/29/2015Q414$1.28$1.30$589.85 million$599.00 millionViewListenView Earnings Details
10/23/2014Q314$1.16$1.27$541.93 million$555.10 millionViewListenView Earnings Details
7/24/2014Q214$1.07$1.12$509.54 million$512.50 millionViewListenView Earnings Details
4/24/2014Q114$1.26$1.53$560.22 million$566.60 millionViewListenView Earnings Details
1/30/2014Q413$0.83$0.87$430.08 million$441.90 millionViewListenView Earnings Details
10/24/2013Q313$0.79$0.83$395.10 million$400.40 millionViewListenView Earnings Details
7/25/2013Q2 2013$0.68$0.73$364.80 million$370.10 millionViewListenView Earnings Details
4/25/2013Q1 2013$0.61$0.65$336.56 million$338.90 millionViewListenView Earnings Details
2/14/2013Q4 2012$0.52$0.60$316.49 million$320.50 millionViewListenView Earnings Details
10/24/2012$0.47$0.60ViewN/AView Earnings Details
7/25/2012$0.36$0.47ViewN/AView Earnings Details
4/24/2012$0.38$0.45ViewN/AView Earnings Details
2/9/2012$0.33$0.41ViewN/AView Earnings Details
10/20/2011$0.28$0.37ViewN/AView Earnings Details
7/21/2011$0.26$0.29ViewN/AView Earnings Details
4/21/2011$0.51$0.59ViewN/AView Earnings Details
2/10/2011$0.50$0.51ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Alexion Pharmaceuticals (NASDAQ:ALXN)
Current Year EPS Consensus Estimate: $4.67 EPS
Next Year EPS Consensus Estimate: $5.84 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161$0.91$0.91$0.91
Q2 20161$1.07$1.07$1.07
Q3 20161$1.17$1.17$1.17
Q4 20161$1.28$1.28$1.28
(Data provided by Zacks Investment Research)


Dividend History for Alexion Pharmaceuticals (NASDAQ:ALXN)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Alexion Pharmaceuticals (NASDAQ:ALXN)
Insider Ownership Percentage: 4.41%
Institutional Ownership Percentage: 96.36%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/14/2016Carsten ThielEVPSell4,584$120.28$551,363.52View SEC Filing  
10/3/2016Carsten ThielEVPSell29$122.41$3,549.89View SEC Filing  
10/3/2016Heidi L WagnerSVPSell120$122.41$14,689.20View SEC Filing  
9/13/2016Carsten ThielEVPSell3,225$128.67$414,960.75View SEC Filing  
9/9/2016Edward MillerSVPSell367$128.32$47,093.44View SEC Filing  
9/6/2016Carsten ThielEVPSell1,000$125.94$125,940.00View SEC Filing  
9/2/2016Julie O'neillEVPSell650$126.29$82,088.50View SEC Filing  
8/30/2016Clare CarmichaelEVPSell1,000$127.76$127,760.00View SEC Filing  
8/22/2016Alvin S ParvenDirectorSell15,000$136.53$2,047,950.00View SEC Filing  
8/15/2016Alvin S ParvenDirectorSell700$135.51$94,857.00View SEC Filing  
8/8/2016Clare CarmichaelEVPSell165$137.14$22,628.10View SEC Filing  
8/8/2016David HallalCEOSell332$137.14$45,530.48View SEC Filing  
8/8/2016Heidi L WagnerSVPSell222$137.14$30,445.08View SEC Filing  
8/8/2016Leonard BellDirectorSell1,010$137.14$138,511.40View SEC Filing  
8/8/2016Vikas SinhaCFOSell277$137.14$37,987.78View SEC Filing  
6/13/2016John B MoriartyEVPSell918$135.72$124,590.96View SEC Filing  
5/16/2016Martin MackayEVPSell4,097$139.20$570,302.40View SEC Filing  
5/13/2016Heidi L WagnerSVPSell53$138.65$7,348.45View SEC Filing  
4/1/2016David HallalCEOSell1,414$135.88$192,134.32View SEC Filing  
2/29/2016Clare CarmichaelEVPSell1,312$138.91$182,249.92View SEC Filing  
2/29/2016David HallalCEOSell2,014$138.93$279,805.02View SEC Filing  
2/29/2016Edward MillerSVPSell329$138.91$45,701.39View SEC Filing  
2/29/2016Leonard BellDirectorSell3,995$138.92$554,985.40View SEC Filing  
2/29/2016Vikas SinhaCFOSell1,122$138.91$155,857.02View SEC Filing  
2/8/2016David HallalCEOSell11,297$140.50$1,587,228.50View SEC Filing  
2/8/2016Heidi L. WagnerSVPSell2,108$140.93$297,080.44View SEC Filing  
2/8/2016Julie O'neillEVPSell2,858$141.83$405,350.14View SEC Filing  
2/8/2016Leonard BellDirectorSell15,872$139.58$2,215,413.76View SEC Filing  
2/8/2016Vikas SinhaCFOSell6,547$140.04$916,841.88View SEC Filing  
2/5/2016Edward MillerSVPSell1,051$143.02$150,314.02View SEC Filing  
12/29/2015Leonard BellDirectorSell35,000$190.66$6,673,100.00View SEC Filing  
12/17/2015Leonard BellDirectorSell70,000$187.69$13,138,300.00View SEC Filing  
12/11/2015Ann M VenemanDirectorSell895$187.48$167,794.60View SEC Filing  
12/11/2015John B. MoriartyEVPSell943$182.73$172,314.39View SEC Filing  
12/8/2015Leonard BellDirectorSell70,000$188.20$13,174,000.00View SEC Filing  
12/8/2015Saqib IslamEVPSell950$190.00$180,500.00View SEC Filing  
11/25/2015Leonard BellDirectorSell35,000$181.89$6,366,150.00View SEC Filing  
10/26/2015Saqib IslamEVPSell1,558$168.44$262,429.52View SEC Filing  
9/9/2015Leonard BellDirectorSell1,050$180.10$189,105.00View SEC Filing  
6/18/2015Leonard BellDirectorSell27,835$179.63$5,000,001.05View SEC Filing  
3/19/2015Leonard BellCEOSell15,952$188.07$3,000,092.64View SEC Filing  
3/2/2015Julie O'neillEVPSell11,665$101.49$1,183,880.85View SEC Filing  
3/2/2015Leonard BellCEOSell1,230$180.34$221,818.20View SEC Filing  
2/10/2015Clare CarmichaelEVPSell1,490$171.15$255,013.50View SEC Filing  
2/10/2015David HallalCOOSell1,980$171.15$338,877.00View SEC Filing  
2/10/2015Leonard BellCEOSell5,740$171.15$982,401.00View SEC Filing  
2/10/2015Vikas SinhaCFOSell1,985$171.15$339,732.75View SEC Filing  
2/9/2015Clare CarmichaelEVPSell1,665$173.75$289,293.75View SEC Filing  
2/9/2015David HallalCOOSell2,920$173.93$507,875.60View SEC Filing  
2/9/2015Leonard BellCEOSell8,660$173.98$1,506,666.80View SEC Filing  
2/9/2015Vikas SinhaCFOSell2,703$174.18$470,808.54View SEC Filing  
2/4/2015David HallalCOOSell1,373$174.18$239,149.14View SEC Filing  
2/4/2015Leonard BellCEOSell5,223$174.29$910,316.67View SEC Filing  
2/4/2015Vikas SinhaCFOSell1,571$174.19$273,652.49View SEC Filing  
12/18/2014David HallalCOOSell5,494$182.03$1,000,072.82View SEC Filing  
12/18/2014Leonard BellCEOSell30,415$179.73$5,466,487.95View SEC Filing  
12/18/2014Vikas SinhaCFOSell5,493$182.08$1,000,165.44View SEC Filing  
12/9/2014Leonard BellCEOSell133,320$198.26$26,432,023.20View SEC Filing  
12/4/2014Clare CarmichaelSVPSell10,000$196.25$1,962,500.00View SEC Filing  
12/4/2014William R KellerDirectorSell5,000$196.25$981,250.00View SEC Filing  
12/3/2014Vikas SinhaCFOSell75,000$198.96$14,922,000.00View SEC Filing  
11/3/2014David HallalCOOSell30,000$190.01$5,700,300.00View SEC Filing  
11/3/2014Martin MackayEVPSell9,375$191.52$1,795,500.00View SEC Filing  
11/3/2014Saqib IslamSVPSell28,125$190.50$5,357,812.50View SEC Filing  
11/3/2014Vikas SinhaCFOSell49,307$192.63$9,498,007.41View SEC Filing  
10/27/2014John B MoriartySVPSell10,000$189.49$1,894,900.00View SEC Filing  
10/27/2014Stephen P SquintoEVPSell5,910$188.58$1,114,507.80View SEC Filing  
10/6/2014John B MoriartySVPSell10,000$179.00$1,790,000.00View SEC Filing  
10/3/2014Stephen P SquintoEVPSell10,025$172.41$1,728,410.25View SEC Filing  
9/26/2014Leonard BellCEOSell60,000$165.12$9,907,200.00View SEC Filing  
9/24/2014Stephen P SquintoEVPSell76$159.50$12,122.00View SEC Filing  
9/18/2014Leonard BellCEOSell44,435$160.60$7,136,261.00View SEC Filing  
9/10/2014Leonard BellCEOSell12,199$165.38$2,017,470.62View SEC Filing  
9/8/2014Leonard BellCEOSell197,801$165.32$32,700,461.32View SEC Filing  
8/27/2014Leonard BellCEOSell5,912$169.17$1,000,133.04View SEC Filing  
8/25/2014Andreas RummeltDirectorSell5,052$170.53$861,517.56View SEC Filing  
8/15/2014Leonard BellCEOSell70,000$167.99$11,759,300.00View SEC Filing  
8/13/2014Leonard BellCEOSell105,000$160.71$16,874,550.00View SEC Filing  
8/12/2014Leonard BellCEOSell80,458$160.16$12,886,153.28View SEC Filing  
8/4/2014David HallalEVPSell1,349$158.00$213,142.00View SEC Filing  
8/4/2014Leonard BellCEOSell5,145$157.88$812,292.60View SEC Filing  
8/4/2014Vikas SinhaCFOSell1,525$157.82$240,675.50View SEC Filing  
7/30/2014Leonard BellCEOSell127,289$162.93$20,739,196.77View SEC Filing  
7/29/2014Leonard BellCEOSell1,200$164.93$197,916.00View SEC Filing  
7/28/2014Leonard BellCEOSell105,600$162.38$17,147,328.00View SEC Filing  
6/20/2014Leonard BellCEOSell90,280$163.60$14,769,808.00View SEC Filing  
6/12/2014Martin MackayEVPSell25,000$166.42$4,160,500.00View SEC Filing  
6/5/2014William R KellerDirectorSell3,425$170.00$582,250.00View SEC Filing  
5/27/2014Leonard BellCEOSell70,000$166.16$11,631,200.00View SEC Filing  
5/20/2014Leonard BellCEOSell70,000$155.96$10,917,200.00View SEC Filing  
5/14/2014Martin MackayEVPSell3,574$160.85$574,877.90View SEC Filing  
5/13/2014Alvin ParvenDirectorSell12,276$160.78$1,973,735.28View SEC Filing  
4/29/2014Leonard BellCEOSell70,000$156.20$10,934,000.00View SEC Filing  
2/10/2014Stephen SquintoEVPSell7,055$158.04$1,114,972.20View SEC Filing  
2/7/2014David HallalEVPSell1,620$155.57$252,023.40View SEC Filing  
2/7/2014Frank WrightSVPSell1,098$155.57$170,815.86View SEC Filing  
2/7/2014Joseph MadriDirectorSell30,000$159.00$4,770,000.00View SEC Filing  
2/7/2014Leonard BellCEOSell4,620$155.56$718,687.20View SEC Filing  
2/4/2014Leonard BellCEOSell11,790$154.50$1,821,555.00View SEC Filing  
2/4/2014Stephen SquintoEVPSell36,989$155.12$5,737,733.68View SEC Filing  
2/4/2014Vikas SinhaCFOSell3,552$154.47$548,677.44View SEC Filing  
1/29/2014Leonard BellCEOSell2,660$133.81$355,934.60View SEC Filing  
1/29/2014Stephen SquintoEVPSell1,118$133.31$149,040.58View SEC Filing  
1/22/2014Leonard BellCEOSell156,436$140.80$22,026,188.80View SEC Filing  
1/10/2014Leonard BellCEOSell19,155$134.98$2,585,541.90View SEC Filing  
12/19/2013Leonard BellCEOSell175,000$126.38$22,116,500.00View SEC Filing  
10/28/2013Stephen P SquintoEVPSell41,037$124.06$5,091,050.22View SEC Filing  
10/28/2013Vikas SinhaCFOSell50,000$122.97$6,148,500.00View SEC Filing  
9/16/2013Joseph MadriDirectorSell30,000$115.00$3,450,000.00View SEC Filing  
9/16/2013Leonard BellCEOSell3,500$115.00$402,500.00View SEC Filing  
9/13/2013Stephen SquintoEVPSell1,000$114.37$114,370.00View SEC Filing  
9/4/2013Leonard BellCEOSell1,850$110.07$203,629.50View SEC Filing  
9/3/2013Leonard BellCEOSell33,150$110.19$3,652,798.50View SEC Filing  
8/30/2013Clare CarmichaelSVPSell1,237$107.58$133,076.46View SEC Filing  
8/16/2013Leonard BellCEOSell140,000$106.08$14,851,200.00View SEC Filing  
8/5/2013Leonard BellCEOSell2,919$116.87$341,143.53View SEC Filing  
8/2/2013Stephen P SquintoEVPSell14,125$115.33$1,629,036.25View SEC Filing  
7/30/2013Leonard BellCEOSell212,737$114.62$24,383,914.94View SEC Filing  
7/30/2013Stephen P SquintoEVPSell1,120$110.86$124,163.20View SEC Filing  
7/12/2013David HallalEVPSell50,000$120.00$6,000,000.00View SEC Filing  
7/1/2013Stephen P SquintoEVPSell44,125$94.97$4,190,551.25View SEC Filing  
5/22/2013R Douglas NorbyDirectorSell40,000$102.77$4,110,800.00View SEC Filing  
5/20/2013William R KellerDirectorSell9,770$103.00$1,006,310.00View SEC Filing  
5/14/2013Leonard BellCEOSell31,113$105.74$3,289,888.62View SEC Filing  
5/13/2013Leonard BellCEOSell41,220$100.85$4,157,037.00View SEC Filing  
4/10/2013Leonard BellCEOSell26,700$100.24$2,676,408.00View SEC Filing  
2/4/2013Leonard BellCEOSell11,880$96.27$1,143,687.60View SEC Filing  
2/4/2013Stephen P SquintoEVPSell2,572$95.68$246,088.96View SEC Filing  
2/4/2013Vikas SinhaCFOSell3,483$95.81$333,706.23View SEC Filing  
1/15/2013Leonard BellCEOSell35,000$98.58$3,450,300.00View SEC Filing  
10/31/2012Patrice CoissacSVPSell84,764$91.16$7,727,086.24View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Alexion Pharmaceuticals (NASDAQ:ALXN)
News IconHot Biotech Stocks Recap: Alexion Pharmaceuticals (NASDAQ ... - The Voice Registrar (NASDAQ:ALXN) - October 21 at 3:28 PM
News IconThe Key Numbers To Watch From Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN)'s Earnings - The Voice Registrar (NASDAQ:ALXN) - October 21 at 3:28 PM logoAlexion Pharmaceuticals : FDA Grants Orphan Drug Designation to ALXN1007 for the Treatment of Patients with Graft-Versus-Host Disease (GVHD) (NASDAQ:ALXN) - October 20 at 9:20 PM logoAlexion (ALXN) Q3 Earnings: Can the Stock Pull a Surprise? (NASDAQ:ALXN) - October 20 at 9:20 PM logoAlexion Graft-Versus-Host Disease Gets ODD (ALXN) (NASDAQ:ALXN) - October 20 at 3:53 PM logoAlexion Pharma (ALXN) Reports FDA Orphan Drug Designation for ... - (NASDAQ:ALXN) - October 20 at 9:17 AM
News IconBiotech news that matter for investors: Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN), Inovio Pharmaceuticals, Inc ... - The Voice Registrar (NASDAQ:ALXN) - October 19 at 4:16 PM logoHow Much Return Could Alexion Offer over the Next 12 months? (NASDAQ:ALXN) - October 19 at 4:16 PM
News IconUpdate on Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) for the day (NASDAQ:ALXN) - October 19 at 8:17 AM
News IconActive Biotech Stock News: Celgene Corporation (CELG), Alexion Pharmaceuticals, Inc. (ALXN) - The Independent Republic (NASDAQ:ALXN) - October 18 at 3:27 PM logoVertex Not the Only Pharmaceutical to See Its Share Price Fall (NASDAQ:ALXN) - October 18 at 3:27 PM logoBUYINS.NET: ALXN SqueezeTrigger Price is $119.13. There is $666,216,285 That Short Sellers Still Need To Cover. (NASDAQ:ALXN) - October 17 at 3:28 PM
News IconBiotech Stocks Worth a Closer Look: Geron Corporation (NASDAQ ... - The Voice Registrar (NASDAQ:ALXN) - October 14 at 11:59 AM
News IconSEC Exclusive: Sabby Management LLC Stake in Alexion Pharmaceuticals INC (ALXN) Lifted as Stock Declined - Chester News (NASDAQ:ALXN) - October 14 at 11:59 AM
News IconHigh Market Cap Stock of the Day – Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) (NASDAQ:ALXN) - October 13 at 8:49 PM
News IconTwo Biotechnology Names Are Hot: Halozyme Therapeutics, Inc ... - The Independent Republic (NASDAQ:ALXN) - October 12 at 3:39 PM
News IconAnalysts Valuations For Two Stocks: Hologic, Inc. (NASDAQ:HOLX), Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) - The Voice Registrar (NASDAQ:ALXN) - October 12 at 3:39 PM
News IconSEC Exclusive: Bokf Has Cut Its Stake in Alexion Pharmaceuticals INC (ALXN) as Market Value Declined - Chester News (NASDAQ:ALXN) - October 12 at 3:39 PM
News IconAlexion Pharmaceuticals, Inc. (NASDAQ:ALXN) Near to Lift Curtain on September 2016 Earnings - The Voice Registrar (NASDAQ:ALXN) - October 12 at 6:45 AM logoAlexion Presents New Long-Term Phase III Data on Kanuma (NASDAQ:ALXN) - October 11 at 3:31 PM
News IconBiotech Stocks Worth a Closer Look: Geron Corporation (NASDAQ:GERN), Alexion Pharmaceuticals, Inc. (NASDAQ ... - The Voice Registrar (NASDAQ:ALXN) - October 10 at 3:25 PM logoAlexion Pharmaceuticals to Report Third Quarter 2016 Results on Thursday, October 27, 2016 (NASDAQ:ALXN) - October 10 at 3:25 PM
News IconLatest Analyst Ratings For Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) - The De Soto Edge (NASDAQ:ALXN) - October 9 at 3:23 PM
News IconBroker Roundup For Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) - The De Soto Edge (NASDAQ:ALXN) - October 7 at 8:16 AM
News IconPay Close Attention To These Analyst Ratings Alexion ... - The Voice Registrar (NASDAQ:ALXN) - October 7 at 8:16 AM logoAlexion Pharma (ALXN) Announces New Long-Term Kanuma Phase 3 Data in LAL-D; ALT Reduction Similar to Placebo - (NASDAQ:ALXN) - October 7 at 8:16 AM logo4:31 pm Alexion Pharma announces that researchers presented new long-term data from an ongoing, open-label extension of the pivotal Phase 3 ARISE trial of Kanuma in children and adults with lysosomal acid lipase deficiency (NASDAQ:ALXN) - October 7 at 8:16 AM logoNew Long-Term Data Presented at WCPGHAN 2016 Show Rapid and Sustained Improvements in Important Markers of Liver Injury and Lipid Abnormalities in Children and Adults with Lysosomal Acid Lipase Deficiency (LAL-D) Treated with Kanuma® (sebel (NASDAQ:ALXN) - October 7 at 8:16 AM
News IconTop Gainers of the Day: Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) from Biotechnology (NASDAQ:ALXN) - October 6 at 9:12 AM logoAlexion Pharmaceuticals, Inc. (NASDAQ:ALXN) Trading Up – Insider Trading Activity (NASDAQ:ALXN) - October 6 at 9:12 AM
News IconBiotech Stocks Worth Chasing: Alexion Pharmaceuticals, Inc. (ALXN), Threshold Pharmaceuticals, Inc. (THLD) - The Independent Republic (NASDAQ:ALXN) - October 5 at 8:16 AM
News IconIs Alexion Pharmaceuticals Inc (ALXN) worth $122.14 based on its ... - Simply Wall St (NASDAQ:ALXN) - October 5 at 8:16 AM
News IconIntraday Active Biotech Stocks News: Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN), ZIOPHARM Oncology, Inc ... - The Voice Registrar (NASDAQ:ALXN) - October 4 at 3:27 PM
News IconActive biotech company shares in the news: Alexion Pharmaceuticals (NASDAQ:ALXN), Galena Biopharma (NASDAQ ... - The Voice Registrar (NASDAQ:ALXN) - October 4 at 8:15 AM
News IconTop Biotechnology Stock Picking: Galena Biopharma, Inc. (GALE), Alexion Pharmaceuticals, Inc. (ALXN) - The Independent Republic (NASDAQ:ALXN) - October 3 at 3:26 PM
News IconAlexion Pharmaceuticals, Inc. (NASDAQ:ALXN) from Biotechnology – Todays Top Gains (NASDAQ:ALXN) - October 3 at 8:12 AM logoCambridge-based Ra Pharmaceuticals files plans for $86M IPO (NASDAQ:ALXN) - October 3 at 8:12 AM
News IconNoteworthy Analyst Ratings of Two Stocks Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN), Amgen, Inc. (NASDAQ ... - The Voice Registrar (NASDAQ:ALXN) - September 30 at 3:54 PM logoWhat Do Analysts Say about Regeneron’s Upside Potential? (NASDAQ:ALXN) - September 30 at 3:54 PM logoAlexion Pharma Receives $194 Price Target - Seeking Alpha (NASDAQ:ALXN) - September 29 at 3:42 PM
News IconTime To Put On The Watch List? - Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN), Dynavax Technologies Corporation ... - The Voice Registrar (NASDAQ:ALXN) - September 28 at 3:25 PM logoWhat’s the Upward Return Potential for BioMarin? (NASDAQ:ALXN) - September 28 at 3:25 PM
News IconTwo Biotechnology Names Are Hot: bluebird bio, Inc. (BLUE), Alexion Pharmaceuticals, Inc. (ALXN) - The Independent Republic (NASDAQ:ALXN) - September 28 at 8:12 AM
News IconAnalysts Valuations For Two Stocks: Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) , NextEra Energy Inc (NYSE:NEE) - The Voice Registrar (NASDAQ:ALXN) - September 27 at 5:49 AM logoJohnson Controls International Now #164 Largest Company, Surpassing Alexion Pharmaceuticals (NASDAQ:ALXN) - September 26 at 8:27 PM logoAlexion Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ALXN-US : September 26, 2016 (NASDAQ:ALXN) - September 26 at 3:27 PM logoAlexion Gets U.K. Approval for High-Cost Drug (ALXN) - Investopedia (NASDAQ:ALXN) - September 24 at 8:47 AM
News IconNews review of 2 biotech stocks: ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP), Alexion Pharmaceuticals, Inc. (NASDAQ ... - The Voice Registrar (NASDAQ:ALXN) - September 23 at 3:53 PM logoAlexion Employees Volunteer Together in Company’s First Global Day of Service (NASDAQ:ALXN) - September 23 at 8:16 AM logoAlexion Pharmaceuticals: Two Steps Forward, One Step Back (NASDAQ:ALXN) - September 22 at 3:25 PM


Alexion Pharmaceuticals (NASDAQ:ALXN) Chart for Sunday, October, 23, 2016

Last Updated on 10/23/2016 by Staff